SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
SANGAMO THERAPEUTICS, INC
Financials through Q1 FY2026, quarter ended Mar 31, 2026Last filing: 10-Q on May 14, 2026
$0.10−0.01 (-8.17%)
Close on Oct 19, 2026
- Market cap
- $39.43M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$0.5388 (−84.19%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
SANGAMO THERAPEUTICS, INC saw revenue fall 45.8% to $34.56M over the twelve months to Mar 31, 2026. Free cash flow was -$90.46M.
Revenue
$34.56M
-45.8% vs. a year earlier
Operating income
-$123.56M
TTM Q1 2026
Free cash flow
-$90.46M
TTM Q1 2026
EPS, diluted
-$0.38
TTM Q1 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Mar 31, 2026
Valuation
- Market cap
- $39.43M
- P/E ratio
- –
- Price to sales
- 1.14
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -229.41%
Fundamentals
- Revenue
- $34.56M
- Net income
- -$123.33M
- EPS, diluted
- -$0.38
- Free cash flow
- -$90.46M
- Book value per share
- -$0.05
- Diluted shares
- 390M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$34.56M-45.8% YoY
Operating income
-$123.56M
Net income
-$123.33M
EPS, diluted
-$0.38
Free cash flow
-$90.46M
Reported periodTrailing twelve months